




## Ectoin® Mouth Wash – Observational study demonstrates great efficacy in treating chemotherapy-induced oral mucositis

### Results


- Ectoin® Mouth Wash significantly reduces typical symptoms of chemotherapy-induced oral mucositis within two weeks.
- 80 % of patients using Ectoin® Mouth Wash were entirely symptom-free after 3 weeks of treatment, compared to only 43 % in the standard arm (Caphosol®).
- Efficacy and tolerability of Ectoin® Mouth Wash is significantly superior compared to standard treatment Caphosol®.
- The overall efficacy as well as the general tolerability of Ectoin® Mouth Wash were assessed as “very good” to “good” in both groups – prophylactic and active use.
- 100 % of the patients using Ectoin® Mouth Wash as preventive treatment would recommend the product to other patients.

Figure 1: Overall efficacy rated on a scale of 0 to 4 after three weeks of treatment



■ Ectoin® Mouth Wash  
■ Caphosol®

Figure 2: Percentage of patients who would recommend the product after the application test



## Study Fact I Ectoin® Mouth Wash – Observational study demonstrates great efficacy in treating chemotherapy-induced oral mucositis

Table: **Brief summary**

<b>Study design</b>	Non-interventional clinical study	
<b>Study population</b>	45 patients undergoing chemotherapy [chemotherapy was applied due to lung cancer (SCLC/NSCLC) or kidney cancer (mRCC) treatment]	
	<ul style="list-style-type: none"> <li>• 10 x prophylactic treatment with Ectoin® Mouth Wash</li> <li>• 20 x active treatment during mucositis with Ectoin® Mouth Wash</li> <li>• 15 x active treatment during mucositis with Caphosol® (standard treatment)</li> </ul>	
<b>Treatment duration</b>	21 days of treatment; application according to instructions for use	
<b>Assessment</b>	<p>Overall efficacy: assessed by the patients after 3 weeks treatment on a 5-point scale: "very bad" = 0, "bad" = 1, "neither good nor bad" = 2, "good" = 3, and "very good" = 4</p> <p>Symptom-specific efficacy: weekly assessment by investigator on a 4-point scale: 0 = none, 1 = mild, 2 = moderate, 3 = severe</p>	
<b>Evaluated symptoms</b>	Dry mucosa	Pain
	Irritation of mucosa	Swelling
	Coated tongue	Ulcer
	Unpleasant breath	Disability to speak
	Decreased saliva release	Difficulty with eating or drinking
<b>Publication</b>	Dao, V.A., Bilstein, A., Overhagen, S. et al. <i>Oncol Ther</i> (2018). <a href="https://doi.org/10.1007/s40487-018-0060-z">https://doi.org/10.1007/s40487-018-0060-z</a>	



"Oral mucositis is one of the most-abundant and severe side effects of cancer treatment which affects the patients' quality of life massively. It is assumed that around 10–50% of patients receiving a standard chemotherapy will develop a mucositis<sup>1)</sup>. In patients receiving high-dose chemotherapy or stem cell transplantation, even 70–80% of all patients<sup>2),3)</sup> will suffer from oral mucositis later on.

We are very proud that we can now offer cancer patients an innovative and effective treatment for oral mucositis whose efficacy proved to go even beyond the efficacy of the well-known standard treatment Caphosol®. Taken preventively, we might even protect patients against this painful condition. We are sure that, with Ectoin® Mouth Wash, we can make life more worth living for cancer patients."

*Dr. Zoltán Baráth, Pulmologist, National Korányi Institute of TBC and Pulmology, Budapest*

<sup>1)</sup> Sonis et al, *Cancer*. 2004 May 1;100(9 Suppl):1995–2025

<sup>2)</sup> Hashmi SK. *Biol Blood Marrow Transplant*. 2015 Sep 24. pii: S1083-8791(15)00639-4

<sup>3)</sup> Vagliano L et al. *Bone Marrow Transplant*. 2011 May;46(5):727–32

**Interested in a license? Please contact our business development team at [bd@bitop.de](mailto:bd@bitop.de)**